Human papillomavirus type 6 L1 protein adsorbed

Human papillomavirus type 6 L1 protein adsorbed · HUMAN PAPILLOMAVIRUS SEROTYPE 6 WHOLE .32 mg/.32mg · Injection, Solution · Boehringer Ingelheim RCV GmbH & Co KG

NDC 68594-0006-99 · .32 mg in 1 BOTTLE, GLASS · BULK INGREDIENT · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (bulk ingredient) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: —
TE code: —
Approval date: —
Patents / exclusivity: —

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Human papillomavirus type 6 L1 protein adsorbed (Injection, Solution)

Labeler	Strength	First seen	Last seen
Boehringer Ingelheim RCV GmbH & Co KG	HUMAN PAPILLOMAVIRUS SEROTYPE 6 WHOLE .32 mg/.32mg	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Human papillomavirus type 6 L1 protein adsorbed — NDC 68594-0006-99," retrieved September 3, 2026, https://drugdashboards.com/drug/68594000699.

Free to cite with attribution — see how the data is put together.